Monkeypox Appears to Recede, but Risks and Uncertainties Linger

September 26, 2022

(New York Times) – Supplies of the vaccine have improved, and federal health officials have begun clinical trials to gain a better understanding of who benefits, and how much, from both the vaccine and the drug used to treat those who become infected. That’s the good news. But unhappily, case numbers are accelerating in a few states and jurisdictions, including Indiana, Virginia and Massachusetts. Black and Hispanic men make up nearly two-thirds of the infected, but only about one-fourth of those vaccinated so far. (Read More)